Tusa Rav Not Better Than Docetaxel for NSCLC ...Middle East

A phase 3 study of the novel antibody-drug conjugate tusamitamab ravtansine in advanced nonsquamous NSCLC yielded disappointing results, but hope for CEACAM5 as a target remains. Medscape Medical News

Hence then, the article about tusa rav not better than docetaxel for nsclc was published today ( Thursday 12/09/2024 - 05:24 PM ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Tusa Rav Not Better Than Docetaxel for NSCLC )

Also on site :

• Not to be dramatic, but LEGO Batman: Legacy of the Dark Knight might be the best Batman game ever
• 15 Shows Like 'Widow's Bay' You Should Watch Next
• This is what super powers must learn from US’ war against Iran